V. Mahler, A. Nast, A. Bauer, D. Becker, J. Brasch, K. Breuer, H. Dickel, H. Drexler, P. Elsner, J. Geier, S. John, B. Kreft, A. Köllner, H. Merk, H. Ott, Silvia Pleschka, Maria Portisch, P. Spornraft-Ragaller, E. Weisshaar, T. Werfel, M. Worm, A. Schnuch, W. Uter
{"title":"S3指南:接触过敏原和药物的皮肤贴片试验-简短版,第1部分","authors":"V. Mahler, A. Nast, A. Bauer, D. Becker, J. Brasch, K. Breuer, H. Dickel, H. Drexler, P. Elsner, J. Geier, S. John, B. Kreft, A. Köllner, H. Merk, H. Ott, Silvia Pleschka, Maria Portisch, P. Spornraft-Ragaller, E. Weisshaar, T. Werfel, M. Worm, A. Schnuch, W. Uter","doi":"10.1111/ddg.13956","DOIUrl":null,"url":null,"abstract":"Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed‐type hypersensitivity. The target audience also includes other health care providers and insurance funds.","PeriodicalId":14702,"journal":{"name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"69","resultStr":"{\"title\":\"S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1\",\"authors\":\"V. Mahler, A. Nast, A. Bauer, D. Becker, J. Brasch, K. Breuer, H. Dickel, H. Drexler, P. Elsner, J. Geier, S. John, B. Kreft, A. Köllner, H. Merk, H. Ott, Silvia Pleschka, Maria Portisch, P. Spornraft-Ragaller, E. Weisshaar, T. Werfel, M. Worm, A. Schnuch, W. Uter\",\"doi\":\"10.1111/ddg.13956\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed‐type hypersensitivity. The target audience also includes other health care providers and insurance funds.\",\"PeriodicalId\":14702,\"journal\":{\"name\":\"JDDG: Journal der Deutschen Dermatologischen Gesellschaft\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"69\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JDDG: Journal der Deutschen Dermatologischen Gesellschaft\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/ddg.13956\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/ddg.13956","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1
Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed‐type hypersensitivity. The target audience also includes other health care providers and insurance funds.